Compare GSK plc (GSK) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Tenet Healthcare Corporation — how do they compare? GSK plc trades at $46.82 (market cap $91.88B), while Tenet Healthcare Corporation trades at $260 (market cap $20.98B). The key difference: GSK plc is far larger — about 4.4× Tenet Healthcare Corporation's market cap, and GSK plc pays a 3.9% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Tenet Healthcare Corporation for 15 Days on average.
| GSK | THC | |
|---|---|---|
Market Cap | $91.88B | $20.98B |
Volume | 7,730,529 | 428,008 |
Sector | Health | Health |
52-Week High | $61.18 | $280.77 |
52-Week Low | $43.24 | $161.37 |
Typical Hold Time | 93 Days | 15 Days |
Enterprise Value | $111.88B | $32.06B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.02, up 0.9% today, with a bearish technical signal but strong fundamentals. The company reported revenue of $32.67B in 2025 with a net income margin of 14.52% and has beaten EPS estimates for three consecutive quarters. Recent news highlights strategic oncology investments and a $750M deal for a cancer therapy, signaling growth initiatives.
The outlook is mixed: solid profitability and a reasonable P/E of 15.1 support value, but technical indicators show bearish pressure near key support at $46. Risks include patent expirations and competitive pressures, while analyst sentiment is cautious with 31% buy ratings. Upside depends on pipeline execution and cost savings.
Tenet Healthcare (THC) trades at $259.83, up 0.53% with a bullish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (ROE 53.31%, net margin 9.9%). Recent news highlights strong cash flow supporting capital returns and upcoming Q3 2026 results on October 29. Valuation appears reasonable with P/E of 10.07 and EV/EBITDA of 5.75.
THC presents a compelling investment case with strong analyst support (81% buy ratings) and 7% upside to consensus target of $283.36. Key catalysts include sustained earnings momentum and efficient capital allocation. Risks include surgical volume pressures and cash flow sustainability concerns amid aggressive buybacks. The stock's current technical setup near pivot point $259 suggests balanced risk-reward.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
